| 发明名称 |
METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS |
| 摘要 |
Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication for effecting neuroprotection in a subject suffering from schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis (MS), Amylotrophic Lateral Sclerosis (ALS), stroke, traumatic brain injury, and/or spinal cord injury. |
| 申请公布号 |
US2014243269(A1) |
申请公布日期 |
2014.08.28 |
| 申请号 |
US201414271617 |
申请日期 |
2014.05.07 |
| 申请人 |
PROTEOSYS AG |
发明人 |
SCHRATTENHOLZ André |
| 分类号 |
C07K14/485;A61K38/18;A61K45/06 |
主分类号 |
C07K14/485 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of effecting neuroprotection in a subject suffering from a condition selected from the group consisting of schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis (MS), Amylotrophic Lateral Sclerosis (ALS), stroke, traumatic brain injury, and spinal cord injury, comprising administering to said subject a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1β. |
| 地址 |
Mainz DE |
